LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist, leads to superior body weight loss in rodent models. Science Translational Medicine , 10(451), eaat8712
Branded products are FDA-approved with extensive trial data
As employers look to more personalized healthcare options for their employees, access to drugs like GLP-1s will play a big role in moving toward more creative benefits strategies
Receive Your Medication STEP 3 3 / 3 Physician guidance for dose adjustments, side-effect management, and long-term success
Flipping the metabolic switch: Understanding and applying health benefits of fasting
Effects of Pentadecapeptide BPC157 Onregional Serotonin Synthesis in the Rat Brain: -Methyl-L-tryptophan Autoradiographicmeasurements